Mild disease may be treated by mesalazine or no treatment with limited number of courses of topical steroids.
The gold standard of care for moderate to severe Crohn’s disease is the Combo therapy, the uninterrupted combination of anti-TNFα monoclonal antibodies and immunosuppressant. However, this kind of treatment raises safety and costs issues.
Indeed, anti-TNFα is the most expensive medication and potential adverse effects are associated with the Combo therapy, namely cancers and possible increase of severe infections. In addition, patients are exposed to class-specific drug complications.
Crohn’s disease (CD) is a chronic inflammatory bowel disease (IBD) affecting the gastro-intestinal tract. CD often begins at young age and lasts the whole life. The prevalence is 20-30% higher for women than for men.
CD is characterized by a sequence of active disease episodes (flare-ups) and remissions of variable duration. The chronicity of CD has a significant impact on patients’ quality of life (QoL).
Genetic susceptibility, modified composition of the gut microbiota and impaired function of the mucosal immune system are the main known contributors to the etiology of CD. However, the primary cause remains unknown.